Circular RNA circ_0074027 indicates a poor prognosis for NSCLC patients and modulates cell proliferation, apoptosis, and invasion via miR-185-3p mediated BRD4/MADD activation
- PMID: 31680319
- DOI: 10.1002/jcb.29484
Circular RNA circ_0074027 indicates a poor prognosis for NSCLC patients and modulates cell proliferation, apoptosis, and invasion via miR-185-3p mediated BRD4/MADD activation
Abstract
Circular RNAs play an imperative role in cancer development and metastasis by regulating oncogenic and tumor-suppressive pathways. However, the role and mechanism of circ_0074027 in non-small-cell lung cancer (NSCLC) have not been elucidated. The expression levels of circ_0074027 were detected by qRT-PCR. The link between circ_0074027 expression and clinicopathologic parameters was analyzed by Fisher's exact test. The prognostic role of circ_0074027 was investigated by Kaplan-Meier and Cox regression analysis. Cell counting kit-8 and flow cytometric assays were utilized to evaluate NSCLC cell proliferation and apoptosis, respectively. Wound scratch and Transwell tests were applied to detect cell migratory and invasive capacities. The interaction potential of circ_0074027 and miR-185-3p was analyzed by the circBank database, and verified by dual-luciferase reporter assay. The downstream gene of miR-185-3p was also investigated. Circ_0074027 was elevated in NSCLC specimens and cell lines. Overexpressed circ_0074027 was related to more advanced TNM stages, poorer differentiation grade, and worse overall survival. Upregulated circ_0074027 increased the proliferation of H1299 cells by inhibiting cell apoptosis. Cell migration and invasion were enhanced after circ_0074027 overexpression. Silenced circ_0074027 caused the opposite effects in the A549 cell line. For mechanism investigation, circ_0074027 directly sponges miR-185-3p to enhance bromodomain-containing protein 4 (BRD4) and MAPK-activating death domain-containing protein (MADD) expression levels at the posttranscriptional level. Furthermore, we found the oncogenic function of circ_0074027 is attributed to its modulation of BRD4 and MADD. Collectively, upregulated circ_0074027 in NSCLC accelerates cell progression via miR-185-3p/BRD4/MADD pathway as a competing endogenous RNA.
Keywords: BRD4; MADD; NSCLC; circRNA; circ_0074027; miR-185-3p.
© 2019 Wiley Periodicals, Inc.
Similar articles
-
Circ_0074027 contributes to the progression of non-small cell lung cancer via microRNA-362-3p/clathrin heavy chain axis.Anticancer Drugs. 2021 Jan 1;32(1):1-10. doi: 10.1097/CAD.0000000000000990. Anticancer Drugs. 2021. PMID: 32932275
-
Circ_0000376 downregulation inhibits the progression of non-small cell lung cancer by mediating the miR-488-3p/BRD4 axis and the PI3K/PKB signaling pathway.Histol Histopathol. 2021 Dec;36(12):1309-1324. doi: 10.14670/HH-18-390. Epub 2021 Nov 3. Histol Histopathol. 2021. PMID: 34730838
-
circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.Thorac Cancer. 2020 Aug;11(8):2196-2208. doi: 10.1111/1759-7714.13527. Epub 2020 Jun 29. Thorac Cancer. 2020. PMID: 32602212 Free PMC article.
-
The Role of circHIPK3 in Tumorigenesis and Its Potential as a Biomarker in Lung Cancer.Cells. 2024 Sep 4;13(17):1483. doi: 10.3390/cells13171483. Cells. 2024. PMID: 39273053 Free PMC article. Review.
-
Circular RNA_0000285: A novel double-edged sword circular RNA in human malignancies.Pathol Res Pract. 2023 Nov;251:154900. doi: 10.1016/j.prp.2023.154900. Epub 2023 Oct 20. Pathol Res Pract. 2023. PMID: 37871444 Review.
Cited by
-
Role of circular RNAs in the diagnosis, regulation of drug resistance and prognosis of lung cancer.Oncol Lett. 2022 Jul 7;24(3):302. doi: 10.3892/ol.2022.13422. eCollection 2022 Sep. Oncol Lett. 2022. PMID: 35949591 Free PMC article. Review.
-
PITX1 plays essential functions in cancer.Front Oncol. 2023 Sep 29;13:1253238. doi: 10.3389/fonc.2023.1253238. eCollection 2023. Front Oncol. 2023. PMID: 37841446 Free PMC article. Review.
-
Circular RNAs in lung cancer: implications for preventing therapeutic resistance.EBioMedicine. 2024 Sep;107:105309. doi: 10.1016/j.ebiom.2024.105309. Epub 2024 Aug 26. EBioMedicine. 2024. PMID: 39191172 Free PMC article. Review.
-
Competing endogenous RNAs in lung cancer.Cancer Biol Med. 2021 Feb 15;18(1):1-20. doi: 10.20892/j.issn.2095-3941.2020.0203. Cancer Biol Med. 2021. PMID: 33628581 Free PMC article. Review.
-
Emerging roles of circular RNAs in non‑small cell lung cancer (Review).Oncol Rep. 2021 Apr;45(4):17. doi: 10.3892/or.2021.7968. Epub 2021 Mar 2. Oncol Rep. 2021. PMID: 33649862 Free PMC article. Review.
References
REFERENCES
-
- Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446-451. https://doi.org/10.1038/nature22364
-
- Zhou F, Nie L, Feng D, Guo S, Luo R. MicroRNA-379 acts as a tumor suppressor in non-small cell lung cancer by targeting the IGF1R-mediated AKT and ERK pathways. Oncol Rep. 2017;38:1857-1866. https://doi.org/10.3892/or.2017.5835
-
- Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 2017;376:2109-2121. https://doi.org/10.1056/NEJMoa1616288
-
- Tang T, Huan L, Zhang S, et al. MicroRNA-212 functions as a tumor-suppressor in human non-small cell lung cancer by targeting SOX4. Oncol Rep. 2017;38:2243-2250. https://doi.org/10.3892/or.2017.5885
-
- Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376:2415-2426. https://doi.org/10.1056/NEJMoa1613493
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources